Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Baxter drug for rare form of haemophilia

Obizur is derived from pig proteins
Baxter building

Baxter has won US approval for its new drug to treat bleeding in a rare form of haemophilia.

The US FDA last week approved Obizur in adults with acquired haemophilia A, a rare and life-threatening form of the bleeding disorder. It is caused by the development of antibodies in the body that attack FVIII, a protein crucial to blood clotting.

Acquired haemophilia A differs from inherited haemophilia A, which is passed on genetically. Instead, people can develop the acquired form of the disorder as part of another health condition, such cancer of pregnancy or due to certain medications, although in half of cases no underlying cause can be found.

Obizur, which was classified as an orphan drug due to the rarity of the condition, works by replacing the affected FVIII protein in the body with a version of FVIII derived from a pig. According to Baxter, this version of factor VIII is less susceptible to attack from human antibodies.

The FDA's decision was based on a phase II/III trial that investigated Obizur's ability to treat serious bleeding episodes in 29 adults with acquired haemophilia A.

All patients treated with the drug demonstrated at least a reduction in bleeding at 24 hours after the first infusion, while 86% had successful treatment of the initial bleeding episode.

Baxter said the drug will be commercially available in the US in the coming months and is currently under regulatory review in Europe and Canada.

The company has as strong heritage in haemophilia, with the division accounting for $3.44bn of Baxter's total $6.56bn biopharma sales for 2013. This was led by haemophilia A therapy Advate, a long-acting version of which is due to be filed by the end of the year.

When Baxter separate its biopharma and medical technology businesses in mid-2015, its biopharma division, which includes its haemophilia interests, will operate under the name Baxalta, while the new Baxter will focus on drug delivery systems and dialysis and hospital products.

27th October 2014

From: Sales, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics